Axitinib is a tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFR-β (IC50 = 1.2, 0.25, 0.29, 1.7, and 1.6 nM, respectively). Through its effects on VEGFRs, it causes regression of fenestrated, VEGFR-rich capillaries in tumors and normal tissue of mice, which is reversed following removal of the inhibitor. Axitinib has shown promise as a therapeutic, in certain cancers and cancer models.
